Payment overview · 2025
General Payments
$5,890.80
83 reported records · 23 companies
Healthcare provider profile · identity verified
John J Kresl, MD, PH.D
Allopathic & Osteopathic Physicians|Radiology|Radiation Oncology · PHOENIX, AZ · NPI 1366418675
Verified facts
What the public records show
CMS Open Payments records show John J Kresl, MD, PH.D received $5,890.80 in general payments during 2025 across 83 reported records.
icotec Medical Inc. accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| icotec Medical Inc. | Unresolved — no canonical attribution shown | $3,154.06 | 53.5% | 27 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $1,146.53 | 19.5% | 14 | 2025 |
| Elekta, Inc. | Unresolved — no canonical attribution shown | $725.32 | 12.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.14 | 2.6% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $96.41 | 1.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.68 | 1.5% | 4 | 2025 |
| Accuray Incorporated | Unresolved — no canonical attribution shown | $66.12 | 1.1% | 1 | 2025 |
| Blue Earth Diagnostics | Unresolved — no canonical attribution shown | $65.92 | 1.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.32 | 1.1% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.36 | 0.8% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $31.98 | 0.5% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.61 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.85 | 0.5% | 1 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $29.22 | 0.5% | 1 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $28.18 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $24.12 | 0.4% | 1 | 2025 |
| BIOPROTECT MEDICAL, INC. | Unresolved — no canonical attribution shown | $22.96 | 0.4% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $19.70 | 0.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.57 | 0.3% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.85 | 0.2% | 1 | 2025 |
| pharmaand GmbH | Unresolved — no canonical attribution shown | $9.24 | 0.2% | 1 | 2025 |
| Digestive Care, Inc. | Unresolved — no canonical attribution shown | $5.93 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,828.72 | 73 |
| Travel and Lodging | $2,062.08 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KONG-TL VBR E, EXPANDABLE BODY, L, 19 MM X 27 - 37 MM Normalized: kong tl vbr e expandable body l 19 mm x 27 37 mm |
Device | icotec Medical Inc. | $1,551.96 | 19 | 2025 |
Source payment records
|
|||||
| KONG-TL VBR, END PLATE, RECTANGULAR, M AND SCREW, 12 X 33 MM Normalized: kong tl vbr end plate rectangular m and screw 12 x 33 mm |
Device | icotec Medical Inc. | $1,551.96 | 19 | 2025 |
Source payment records
|
|||||
| KONG-TL VBR, END PLATE, ROUND, L AND SCREW, 12 X 43 MM Normalized: kong tl vbr end plate round l and screw 12 x 43 mm |
Device | icotec Medical Inc. | $1,551.96 | 19 | 2025 |
Source payment records
|
|||||
| VADER PEDICLE SYSTEM 6.0, SCREW, Carbon/PEEK, POLYAX., FEN., O 5.5 X 45 MM Normalized: vader pedicle system 6 0 screw carbon peek polyax fen o 5 5 x 45 mm |
Device | icotec Medical Inc. | $1,551.96 | 19 | 2025 |
Source payment records
|
|||||
| VADER PEDICLE SYSTEM, ROD, Carbon/PEEK, CURVED, 6.0 R450 X 200 MM Normalized: vader pedicle system rod carbon peek curved 6 0 r450 x 200 mm |
Device | icotec Medical Inc. | $1,551.96 | 19 | 2025 |
Source payment records
|
|||||
| Varian Ethos Treatment Planning Normalized: varian ethos treatment planning |
Device | Siemens Medical Solutions USA, Inc. | $576.41 | 7 | 2025 |
Source payment records
|
|||||
| ELEKTA UNITY Normalized: elekta unity |
Device | Elekta, Inc. | $431.37 | 5 | 2025 |
Source payment records
|
|||||
| Eclipse Treatment Planning System for External Beam Radiation Therapy Normalized: eclipse treatment planning system for external beam radiation therapy |
Device | Siemens Medical Solutions USA, Inc. | $154.78 | 2 | 2025 |
Source payment records
|
|||||
| ELEKTA MEDICAL LINEAR ACCELERATOR Normalized: elekta medical linear accelerator |
Device | Elekta, Inc. | $142.95 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $124.70 | 5 | 2025 |
Source payment records
|
|||||
| ARIA Radiation Therapy Management Software Normalized: aria radiation therapy management software |
Device | Siemens Medical Solutions USA, Inc. | $121.07 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $101.53 | 5 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $86.68 | 4 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $86.68 | 4 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $76.28 | 3 | 2025 |
Source payment records
|
|||||
| CyberKnife System Normalized: cyberknife system |
Device | Accuray Incorporated | $66.12 | 1 | 2025 |
Source payment records
|
|||||
| POSLUMA Normalized: posluma |
Drug | Blue Earth Diagnostics | $65.92 | 2 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $64.32 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $64.32 | 3 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $45.36 | 2 | 2025 |
Source payment records
|
|||||
| TrueBeam Normalized: truebeam |
Device | Siemens Medical Solutions USA, Inc. | $38.14 | 1 | 2025 |
Source payment records
|
|||||
| EDGE Normalized: edge |
Device | Siemens Medical Solutions USA, Inc. | $36.25 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $30.61 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.85 | 1 | 2025 |
Source payment records
|
|||||
| PYLARIFY Normalized: pylarify |
Drug | PROGENICS PHARMACEUTICALS, INC. | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $24.12 | 1 | 2025 |
Source payment records
|
|||||
| BIOPROTECT BALLOON IMPLANT SYSTEM Normalized: bioprotect balloon implant system |
Device | BIOPROTECT MEDICAL, INC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Rubraca Normalized: rubraca |
Drug | pharmaand GmbH | $9.24 | 1 | 2025 |
Source payment records
|
|||||
| Pertzye Normalized: pertzye |
Drug | Digestive Care, Inc. | $5.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 11 |
| Bicalutamide | Bicalutamide | 31 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,890.80 · 83 records | icotec Medical Inc. | ARIA Radiation Therapy Management Software, BIOPROTECT BALLOON IMPLANT SYSTEM, CyberKnife System, EDGE, ELEKTA MEDICAL LINEAR ACCELERATOR, ELEKTA UNITY, EPKINLY, ERLEADA, Eclipse Treatment Planning System for External Beam Radiation Therapy, FRUZAQLA, Gavreto, IMBRUVICA, IMFINZI, KONG-TL VBR E, EXPANDABLE BODY, L, 19 MM X 27 - 37 MM, KONG-TL VBR, END PLATE, RECTANGULAR, M AND SCREW, 12 X 33 MM, KONG-TL VBR, END PLATE, ROUND, L AND SCREW, 12 X 43 MM, LUTATHERA, Nubeqa, ORGOVYX, Optune Lua (NovoTTF-200T), PLUVICTO, POSLUMA, PYLARIFY, Pertzye, Polivy, Rezlidhia, Rubraca, Stivarga, TALZENNA, TAVALISSE, Trelstar, TrueBeam, VADER PEDICLE SYSTEM 6.0, SCREW, Carbon/PEEK, POLYAX., FEN., O 5.5 X 45 MM, VADER PEDICLE SYSTEM, ROD, Carbon/PEEK, CURVED, 6.0 R450 X 200 MM, Varian Ethos Treatment Planning, Vitrakvi, XTANDI, clonoSEQ | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error